Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Conavi Medical ( (TSE:CNVI) ) has issued an update.
Conavi Medical announced the results of its annual general meeting, where all nominated directors were elected and PricewaterhouseCoopers LLP was appointed as auditors. The company also adopted amendments to its Omnibus Equity Incentive Plan, removing restrictions on insider participation to enhance flexibility in attracting and retaining key personnel. These changes are expected to support the company’s growth, although they await TSXV approval.
More about Conavi Medical
Conavi Medical is a commercial stage medical device company specializing in imaging technologies for minimally invasive cardiovascular procedures. Their flagship product, the Novasight Hybrid™ System, uniquely combines intravascular ultrasound and optical coherence tomography for coronary artery imaging, with regulatory approvals from the FDA, Health Canada, and other international bodies.
YTD Price Performance: -14.00%
Average Trading Volume: 4,987
Technical Sentiment Signal: Strong Buy
Current Market Cap: $6.98M
For a thorough assessment of CNVI stock, go to TipRanks’ Stock Analysis page.